The influence of carrier and drug morphology on drug delivery from dry powder formulations

被引:132
|
作者
Larhrib, H
Martin, GP
Marriott, C
Prime, D
机构
[1] Kings Coll London, Dept Pharm, London SE1 9NN, England
[2] GlaxoSmithKline Ltd, Ware SG12 0DP, Herts, England
关键词
dry powder inhalers; lactose; salbutamol sulphate; decomposition; crystallisation; elongation ratio; surface smoothness; flow properties; fine particle fraction;
D O I
10.1016/S0378-5173(03)00156-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Lactose was crystallised either from neutralised Carbopol 934 gel or from water-ethanol solution without stirring, with a view to obtaining lactose alpha-monohydrate of favourable shape and smooth surface, suitable for use as carriers in formulations for dry powder inhalers (DPIs). Crystallisation of salbutamol sulphate was carried out in the presence of water, lecithin and ethanol to form salbutamol crystals with defined shape and smooth surface. The crystals formed were needle-shaped, with a length of less than 6 mum and a width between 0.5 and 1 mum. DSC and TGA showed that lactose crystals produced from Carbopol gel or from water-ethanol solution existed as alpha-lactose monohydrate. The DSC thermograms of micronised and crystallised salbutamol sulphate showed two similar endothermic transitions at 200 and 290degreesC, respectively. The first transition was initially thought to correspond to the melting of salbutamol sulphate. However, the shape of the particles as observed by optical microscopy was not altered after heating the sample to 250degreesC, suggesting that no transition from solid to liquid state occurred at 200degreesC. This was confirmed by observations made using hot stage microscopy. The two endothermic transitions are suggested to correspond to the decomposition of the salbutamol sulphate molecule. The elongation ratio of the commercial lactose crystals, lactose crystallised from Carbopol and from water-ethanol were 1.69+/-0.05, 2.01+/-0.13 and 6.25+/-0.17, respectively. As the elongation ratio increased the flow properties of the carrier were affected detrimentally and this consequently reduced the content uniformity of salbutamol sulphate and drug emission from the inhaler device. Whereas, increasing the elongation ratio of the carrier or drug improved the deposition profiles of salbutamol sulphate, suggesting that the more elongated particles would be more aerodynamic and favour deep lung penetration. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:283 / 296
页数:14
相关论文
共 50 条
  • [1] The influence of carrier morphology on drug delivery by dry powder inhalers
    Zeng, XM
    Martin, GP
    Marriott, C
    Pritchard, J
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 200 (01) : 93 - 106
  • [2] Lactose as a carrier in dry powder formulations: The influence of surface characteristics on drug delivery
    Zeng, XM
    Martin, GP
    Marriott, C
    Pritchard, J
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 90 (09) : 1424 - 1434
  • [3] The influence of drug morphology on the aerosolisation efficiency of dry powder inhaler formulations
    Adi, Handoko
    Traini, Daniela
    Chan, Hak-Kim
    Young, Paul M.
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 97 (07) : 2780 - 2788
  • [4] Development of dry powder inhaler formulations for drug delivery systems
    Akdag, Yagmur
    [J]. JOURNAL OF RESEARCH IN PHARMACY, 2019, 23 (06): : 973 - 987
  • [5] Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations
    Knap, Karolina
    Kwiecien, Konrad
    Reczynska-Kolman, Katarzyna
    Pamula, Elzbieta
    [J]. REGENERATIVE BIOMATERIALS, 2023, 10
  • [6] DRY POWDER INHALER FORMULATIONS-EFFECT OF CARRIER SIZE ON THE DRUG DISPERSION
    Tuli, Rinku A.
    Dargaville, Tim R.
    George, Graeme A.
    Islam, Nazrul
    [J]. JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2013, 26 (05) : A3 - A3
  • [7] Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug
    Sethuraman V.V.
    Hickey A.J.
    [J]. AAPS PharmSciTech, 3 (4)
  • [8] Drug delivery to the lungs from dry powder inhalers
    Newman, SP
    [J]. CURRENT OPINION IN PULMONARY MEDICINE, 2003, 9 : S17 - S20
  • [9] Devices for Dry Powder Drug Delivery to the Lung
    Berkenfeld, Kai
    Lamprecht, Alf
    McConville, Jason T.
    [J]. AAPS PHARMSCITECH, 2015, 16 (03): : 479 - 490
  • [10] Effervescent dry powder for respiratory drug delivery
    Ely, Leticia
    Roa, Wilson
    Finlay, Warren H.
    Lobenberg, Raimar
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2007, 65 (03) : 346 - 353